A Randomized, Open-label, Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
Latest Information Update: 26 Mar 2025
At a glance
- Drugs HR 19042 (Primary)
- Indications Autoimmune hepatitis
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 24 Mar 2025 Status changed from recruiting to completed.
- 17 Aug 2023 Status changed from not yet recruiting to recruiting.
- 29 Jul 2022 New trial record